The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 6 May 2002. doi:10.1084/jem.20011701
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 607K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Houlard, M.
Right arrow Articles by Varin-Blank, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Houlard, M.
Right arrow Articles by Varin-Blank, N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© Rockefeller University Press, 0022-1007/2002/5/1115/ $5.00
The Journal of Experimental Medicine, Volume 195, Number 9, May 6, 2002 1115-1127

Vav1 Is a Component of Transcriptionally Active Complexes

Martin Houlard1, Ramachandran Arudchandran2, Fabienne Regnier-Ricard1, Antonia Germani1, Sylvie Gisselbrecht1, Ulrich Blank3, Juan Rivera2 and Nadine Varin-Blank1

1 Unité Inserm 363, Oncologie Cellulaire et Moléculaire, Institut Cochin de Génétique Moléculaire, Hopital Cochin, Paris 75014, France
2 Molecular Inflammation Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892
3 Unité d'Immuno-allergie, Institut Pasteur, Paris 75015, France

Address correspondence to Dr. N. Varin-Blank, U363 Inserm, ICGM, Hopital Cochin, 27 rue du Fg St Jacques, 75014 Paris, France. Phone: 33-1-40-51-65-40; Fax: 33-1-40-57-65-70; E-mail: varin{at}cochin.inserm.fr, and Dr. J. Rivera, NIAMS, NIH, Bg 10 Room 9N-228, Bethesda, MD 20892. Phone: 301-496-7592; Fax: 301-480-1580; E-mail: juan_rivera{at}nih.gov

The importance of the hematopoietic protooncogene Vav1 in immune cell function is widely recognized, although its regulatory mechanisms are not completely understood. Here, we examined whether Vav1 has a nuclear function, as past studies have reported its nuclear localization. Our findings provide a definitive demonstration of Vav1 nuclear localization in a receptor stimulation–dependent manner and reveal a critical role for the COOH-terminal Src homology 3 (SH3) domain and a nuclear localization sequence within the pleckstrin homology domain. Analysis of DNA-bound transcription factor complexes revealed nuclear Vav1 as an integral component of transcriptionally active nuclear factor of activated T cells (NFAT)- and nuclear factor (NF){kappa}B-like complexes, and the COOH-terminal SH3 domain as being critical in their formation. Thus, we describe a novel nuclear role for Vav1 as a component and facilitator of NFAT and NF{kappa}B-like transcriptional activity.

Key Words: Vav • nuclear translocation • nuclear factor of activated T cells • calcium influx • protein subdomains


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS